¹Department of Gastroenterological Surgery and General Surgery, Haydarpaşa Numune Education and Research Hospital, Haydarpasa 34668 İstanbul, Turkey
²Department of Gastroenterological Surgery, Kartal Koşuyolu Education and Research Hospital, Cevizli 34865 İstanbul, Turkey
³Department of General Surgery, Haydarpaşa Numune Education and Research Hospital, Haydarpaşa 34668 İstanbul, Turkey
⁴Marmara University Vocational School of Health Related Professions, Haydarpasa 34668 Istanbul, Turkey
⁵Departments of Histology-Embryology, School of Medicine, Marmara University, Haydarpaşa 34668 İstanbul, Turkey
⁶Near East University, Faculty of Dentistry, Department of Pharmacology, 99138 Lefkoşa, Turkish Republic of Northern Cyprus DOI : 10.12991/jrp.2018.83 The aim of this study was to evaluate the possible protective effect of spironolactone (SPL) and role of the Na-K ATPase pump on intestinal ischemia/reperfusion injury. In our study, the period of ischemia was established by clamping the mesenteric artery for 45 minunder anesthesia in Wistar albino rats and the animals left for reperfusion at the end of this period were decapitated after one hour. Spironolactone (20 mg kg-1) was administered orally for three days before ischemia, 30 minbefore ischemia. The control group rats were subjected to the Sham operation and administered saline solution. TNF-α and IL-1β levels were measured in the serum samples. Ileal Na+/K+-ATPase, myeloperoxidase (MPO) analysis were performed. Structural injury was assessed histopathologically. Ischemia/reperfusion increased serum TNF-α and IL-1β levels together with MPO activity, whereas these values were maintained at the control group levels through SPL activation. However, ischemia/reperfusion decreased Na+/K+-ATPase activity in ileal tissues; however, these parameters were found to be significantly increased with SPL activation. The protective effect of SPL against ischemia/reperfusion injury by different mechanisms, mainly the activity of the Na+/K+-ATPase pump, suggests that this nontoxic agent may constitute a new clinical therapeutic principle. Keywords : Intestinal ischemia/reperfusion; inflammation; Na+/K+-ATPase; spironolactone